WHO Recommends AstraZeneca-Oxford COVID-19 Vaccine

 

The World Health Organization on Wednesday issued an interim recommendation in favor of the AstraZeneca-Oxford adenovirus-vectored COVID-19 vaccine.

The agency advises that adults aged 18 and older receive two doses, spaced 8 to 12 weeks apart. If the second dose is given less than 4 weeks after the first, it does not need to be repeated. If more than 12 weeks pass after the first dose, the second dose should be given as soon as possible.

In terms of particular subgroups, the WHO recommends the vaccine for people with comorbidities that place them at increased risk for severe COVID-19, including those with cardiovascular disease, diabetes, obesity, and respiratory disease. For pregnant individuals, the agency says the vaccine should be given only to those in other risk groups, such as health care workers or those with the aforementioned comorbidities. For information on other patient populations, see p. 48 of the recommendations linked below.

WHO interim recommendations on AstraZeneca-Oxford vaccine 


The World Health Organization on Wednesday issued an interim recommendation in favor of the AstraZeneca-Oxford adenovirus-vectored COVID-19 vaccine.

The agency advises that adults aged 18 and older receive two doses, spaced 8 to 12 weeks apart. If the second dose is given less than 4 weeks after the first, it does not need to be repeated. If more than 12 weeks pass after the first dose, the second dose should be given as soon as possible.

In terms of particular subgroups, the WHO recommends the vaccine for people with comorbidities that place them at increased risk for severe COVID-19, including those with cardiovascular disease, diabetes, obesity, and respiratory disease. For pregnant individuals, the agency says the vaccine should be given only to those in other risk groups, such as health care workers or those with the aforementioned comorbidities. For information on other patient populations, see p. 48 of the recommendations linked below.

WHO interim recommendations on AstraZeneca-Oxford vaccine (Free PDF)

NEJM COVID-19 Vaccine Resource Center (Free)

Background: WHO interim recommendations on Moderna vaccine (Free PDF)

Share on Facebook   Tweet E-mail  

Your NEJM Group Today: Genetic Diversity & Black Health / Hepatitis C Vaccine Trial / Urogynecologist & Nocturnist Opportunities

By the Editors

Check out today’s highlights from NEJM Group:

New England Journal of Medicine: Five Black male geneticists offer their perspectives on genetics, race, ancestry, and health disparities affecting the Black community.

NEJM Journal Watch: In a phase 1/2 study among people who’d recently injected drugs and were not infected with hepatitis C virus (HCV), an experimental vaccine was safe but did not prevent chronic HCV infection.

NEJM CareerCenter:

  • Urogynecologist: The Northwell Health Center for Women’s Health and The Zucker School of Medicine are seeking a full-time physician to join their urogynecology division at Staten Island University Hospital in New York.
  • Nocturnist: RWJBarnabas Health is seeking nocturnists for per diem and full-time shifts at Saint Barnabas Medical Center in Livingston and Robert Wood Johnson University Hospital in Rahway, New Jersey.

NEJM Medicine & Society article (Free)

NEJM Journal Watch summary (Free)

NEJM CareerCenter urogynecology listing (Free)

NEJM CareerCenter nocturnist listing (Free)

retro

Share on Facebook   Tweet E-mail  

retro